TransMedics Group (TMDX) Stock Forecast & Price Target

Compare

1,658 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMDX Analyst Ratings

Moderate Buy

8 Buy

3 Hold

0 Sell

Based on 11 analysts giving stock ratings to

TransMedics

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$144.11

▲(19.96% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $144.11 with a high forecast of $170.00 and a low forecast of $115.00. The average price target represents a 19.96% change from the last price of $120.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","116":"$116","171":"$171","88.5":"$88.5","143.5":"$143.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$144.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,88.5,116,143.5,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,119.12923076923077,123.36846153846153,127.6076923076923,131.84692307692308,136.08615384615385,140.32538461538462,144.5646153846154,148.80384615384617,153.0430769230769,157.28230769230768,161.52153846153846,165.76076923076923,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,117.1376923076923,119.38538461538462,121.63307692307693,123.88076923076923,126.12846153846155,128.37615384615384,130.62384615384616,132.87153846153848,135.11923076923077,137.3669230769231,139.6146153846154,141.8623076923077,{"y":144.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,114.89846153846153,114.90692307692308,114.91538461538461,114.92384615384616,114.93230769230769,114.94076923076923,114.94923076923077,114.95769230769231,114.96615384615384,114.97461538461539,114.98307692307692,114.99153846153847,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":144.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$170.00

Average Price Target$144.11

Lowest Price Target$115.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

$170

Buy

41.51%

Upside

Reiterated

10/21/25

Buy Rating for TransMedics Group: Transformative Organ Care System Enhances Transplant Efficiency and Expands Usable Organ SupplyWe are tracking monthly U.S. heart, liver, and lung transplant volumes and TransMedics Aviation flights. TMDX has moved beyond the early innings of the Organ Care System (OCS) and National OCS Program (NOP) launches, so quarterly revenue performances have become levered to US transplant market trends and TransMedics Aviation flight runs, which face known annual seasonality headwinds in 3Q.

Lila Implantra

TR | OpenAI - 4o

$125→$130

Buy

8.22%

Upside

Reiterated

10/17/25

AI Generated ArticleAI Generated Article

Thomas Stephan

Stifel Nicolaus

$115

Hold

-4.27%

Downside

Reiterated

10/14/25

Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)

William Plovanic

Canaccord Genuity

$142

Buy

18.21%

Upside

Reiterated

10/13/25

TransMedics Group (TMDX) Gets a Buy from Canaccord Genuity

Young Li

Jefferies

$145

Buy

20.70%

Upside

Initiated

10/13/25

Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects

Daniel Markowitz CFA

Evercore ISI

$155

Buy

29.03%

Upside

Reiterated

10/07/25

TransMedics added to 'Tactical Underperform' list at Evercore ISITransMedics added to 'Tactical Underperform' list at Evercore ISI

Suraj Kalia

Oppenheimer

$150

Buy

24.86%

Upside

Reiterated

10/03/25

Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/03/25

TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales FluctuationsWe believe TransMedics may fall modestly short of consensus sales estimates this quarter, mainly due to typical seasonal weakness in industry transplant volumes. More specific, based on our analysis of flight volume trends in the period (detailed below), we believe third-quarter revenue could approximate $140 million, which is roughly 4% below the current Street estimate of $145.3 million. Our projections are further supported by monthly organ transplant activity through the third quarter (also detailed below), which also indicates seasonal industry weakness.

Michael Matson

Needham

―

Hold

―

Reiterated

09/23/25

Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections

Patrick Wood

Morgan Stanley

$123

Hold

2.39%

Upside

Reiterated

09/18/25

Hold Rating on TransMedics Amid Regulatory Changes in Organ Transplant Sector

Matthew O'Brien

Piper Sandler

$145

Buy

20.70%

Upside

Reiterated

09/03/25

Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$148→$152

Buy

26.53%

Upside

Reiterated

07/31/25

TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird

Allen Gong

J.P. Morgan

$81→$114

Hold

-5.10%

Downside

Reiterated

05/09/25

TransMedics Group (TMDX) PT Raised to $114 at JPMorganJPMorgan analyst Allen Gong raised the price target on TransMedics Group (NASDAQ: TMDX) to $114.00 (from $81.00) while maintaining a Neutral rating.

Unknown Analyst

Nephron

Not Ranked

Nephron

$105

Buy

-12.59%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

$170

Buy

41.51%

Upside

Reiterated

10/21/25

Lila Implantra

TR | OpenAI - 4o

$125→$130

Buy

8.22%

Upside

Reiterated

10/17/25

AI Generated ArticleAI Generated Article

Thomas Stephan

Stifel Nicolaus

$115

Hold

-4.27%

Downside

Reiterated

10/14/25

Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)

William Plovanic

Canaccord Genuity

$142

Buy

18.21%

Upside

Reiterated

10/13/25

TransMedics Group (TMDX) Gets a Buy from Canaccord Genuity

Young Li

Jefferies

$145

Buy

20.70%

Upside

Initiated

10/13/25

Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects

Daniel Markowitz CFA

Evercore ISI

$155

Buy

29.03%

Upside

Reiterated

10/07/25

TransMedics added to 'Tactical Underperform' list at Evercore ISITransMedics added to 'Tactical Underperform' list at Evercore ISI

Suraj Kalia

Oppenheimer

$150

Buy

24.86%

Upside

Reiterated

10/03/25

Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/03/25

Michael Matson

Needham

―

Hold

―

Reiterated

09/23/25

Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections

Patrick Wood

Morgan Stanley

$123

Hold

2.39%

Upside

Reiterated

09/18/25

Hold Rating on TransMedics Amid Regulatory Changes in Organ Transplant Sector

Matthew O'Brien

Piper Sandler

$145

Buy

20.70%

Upside

Reiterated

09/03/25

Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$148→$152

Buy

26.53%

Upside

Reiterated

07/31/25

TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird

Allen Gong

J.P. Morgan

$81→$114

Hold

-5.10%

Downside

Reiterated

05/09/25

Unknown Analyst

Nephron

Not Ranked

Nephron

$105

Buy

-12.59%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

1 Month

xxx

Success Rate

19/31 ratings generated profit

Average Return

+5.89%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.29% of your transactions generating a profit, with an average return of +5.89% per trade.

3 Months

xxx

Success Rate

19/31 ratings generated profit

Average Return

+15.33%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.29% of your transactions generating a profit, with an average return of +15.33% per trade.

1 Year

William PlovanicCanaccord Genuity

Success Rate

23/31 ratings generated profit

Average Return

+47.94%

reiterated a buy rating 10 days ago

Copying William Plovanic's trades and holding each position for 1 Year would result in 74.19% of your transactions generating a profit, with an average return of +47.94% per trade.

2 Years

xxx

Success Rate

26/31 ratings generated profit

Average Return

+94.19%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +94.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMDX has received 29 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 144.11.

Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.36 with a range of $0.24 to $0.51. The previous quarter’s EPS was $0.92. TMDX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $144.62M with a range of $139.40M to $149.00M. The previous quarter’s sales results were $157.37M. TMDX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 144.11.

What is TMDX’s upside potential, based on the analysts’ average price target?

TransMedics Group Inc has 19.96% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMDX a Buy, Sell or Hold?

TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.

What is TransMedics Group Inc’s price target?

The average price target for TransMedics Group Inc is 144.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $170.00 ,the lowest forecast is $115.00. The average price target represents 19.96% Increase from the current price of $120.13.

What do analysts say about TransMedics Group Inc?

TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

TransMedics Group (TMDX) Stock Forecast & Price Target

TMDX Analyst Ratings

TMDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TransMedics Group

TMDX Analyst Recommendation Trends

TMDX Financial Forecast

TMDX Earnings Forecast

TMDX Sales Forecast

TMDX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts